Marketing

American leaders' distrust in science a 'dangerous situation,' BIO chair says

John Maraganore, the chair of biotech's largest trade group, said he's concerned the recent controversy over gene-edited babies could trigger knee-jerk reactions.

By Andrew Dunn • Dec. 14, 2018
BIO chair: More drugmakers should pledge to not hike prices

"The industry can do better," Alnylam CEO John Maraganore told BioPharma Dive, arguing that scrutiny of rising drug prices isn't going away.

By Andrew Dunn • Dec. 13, 2018
Kaléo, facing criticism, launches generic overdose treatment at cut price

At $178 for a pack of two, Kaléo's authorized copy of its own Evzio will cost far less than the $4,100 list price it set for the branded version.

By Ned Pagliarulo • Dec. 12, 2018
WPP plots return to growth through 'simpler offer,' refreshes brand identity

The holding group plans to focus squarely on four business areas going forward, but more agency mergers don't appear to be in the cards for now.

By Peter Adams • Dec. 11, 2018
Roche wins key cancer drug approval, but taking on Merck remains a challenge

Despite Tecentriq's OK in frontline metastatic lung cancer, one Wall Street analyst cut sales forecasts for the drug by billions over the next five years.

By Ned Pagliarulo • Dec. 11, 2018
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

ViiV and majority owner GSK are focused on two-drug regimens, while rival Gilead is betting big on its recently approved triplet Biktarvy.

By Jacob Bell • Dec. 11, 2018
J&J's Actelion pays out $360M to resolve kickback claims

The Justice Department claimed the pharma donated to a charity to help pay Medicare patients' copays for its drugs.

By Suzanne Elvidge • Dec. 10, 2018
FedEx, Walgreens partner for next-day delivery of prescription drugs

The company's move is designed to head off Amazon's entry into home delivery as well as compete with CVS' similar service.

By Andy Burt • Dec. 07, 2018
AbbVie nets 7th Humira biosimilar deal, pushing Pfizer entry to 2023

The settlement allows Pfizer to launch its copy in the U.S. at the end of 2023; a European launch can go ahead as soon as approval comes through.

By Suzanne Elvidge • Dec. 05, 2018
Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

Looming over clinical victories seen at ASH was a problematic question: How exactly will health systems pay for these powerful yet pricey therapies?

By Jacob Bell • Dec. 05, 2018
Dive Awards
Drug Launch of the Year: Amgen and Novartis' Aimovig

Choosing a lower-than-expected price was an unusual, disruptive move, but one that could pay off as Amgen and Novartis fend off rivals.

By Andrew Dunn • Dec. 03, 2018
Dive Awards
Biotech of the Year: Spark Therapeutics

The biotech's gene therapy Luxturna, priced at $850,000 per patient, is testing a healthcare system not designed for transformative, one-time treatments.

By Jacob Bell • Dec. 03, 2018
Merck increased list prices on Keytruda, Gardasil in November

The pharmaceutical giant made a pricing pledge this summer. A company spokesperson contended these price hikes are "fully consistent" with the plan.

By Andrew Dunn • Nov. 29, 2018
CVS, Aetna finalize megamerger

The acquisition, worth $69 billion excluding debt, creates the second biggest private company by revenue after Walmart.

By Rebecca Pifer • Nov. 28, 2018
Q&A
5 rheumatologists discuss the evolving landscape of RA treatment

Drug pricing, JAK inhibitors and more personalized therapies are top of mind for many rheumatoid arthritis doctors.

By Jacob Bell • Nov. 26, 2018
Drugmakers vie to capture slice of rheumatoid arthritis market

TNF inhibitors like Humira have long held top positions. But not all patients respond and some still aren't treated with biologics — fueling further investment in the space.

By Ned Pagliarulo • Nov. 26, 2018
Drug costs pushed one-third of Americans to skip a prescription in the past year: GoodRx

Nearly all respondents to a recent survey said they had health insurance, yet 42% noted they were still having difficulty paying for medications.

By Jacob Bell • Nov. 26, 2018
Court opens path for Dr. Reddy's to launch generic Suboxone

A U.S. federal appeals court threw out a preliminary injunction that had blocked the generics maker from launching a copy of Indivior's opioid treatment.

By Andrew Dunn • Nov. 21, 2018
Novartis confident in Gilenya despite FDA call out

Regulators identified 35 cases where patients experienced severely increased disability after going off Gilenya, spurring a label update about potential risks.

By Jacob Bell • Nov. 21, 2018
Sandoz, Pear begin selling digital substance use treatment

The FDA called it the first mobile medical app to treat substance use disorders.

By Nick Paul Taylor • Nov. 21, 2018
Sobi's late-breaking ASH data also spurs an approval

Emapalumab, to be branded as Gamifant, is now OK'd in the U.S. for patients with a rare inflammatory disease known as primary HLH.

By Jacob Bell • Nov. 20, 2018
Kaleo under fire for price hikes on naloxone treatment

Kaleo raised its price for Evzio from $575 to $4,100 in fewer than three years. Now, the company's tactics are the focus of a new Senate report and a "60 Minutes" segment.

By Andrew Dunn • Nov. 19, 2018
Pfizer tests Trump with plans to hike prices on 41 drugs

Last month, Pfizer CEO Ian Read indicated the pharma would soon return to "business as normal" after a rare reversal on price hikes made in July.

By Ned Pagliarulo • Nov. 16, 2018
7 drugs that raised eyebrows in Q3

Biosimilars began to bite into blockbuster franchises, while newer products propped up sales at Sanofi, Regeneron and GSK.

By Jacob Bell • Nov. 15, 2018
California, Massachusetts go toe-to-toe for title of best biotech hub

For yet another year, the two states put out reports showcasing statistics that back why they ought to be called biopharma's No. 1 hub.

By Andrew Dunn • Nov. 14, 2018